Not all clots are created equal: a review of deficient thrombolysis with tissue plasminogen activator (tPA) in patients with metabolic syndrome
CI Mosimah, PJ Murray, JW Simpkins - International Journal of …, 2019 - Taylor & Francis
Metabolic syndrome is a cluster of cardiovascular risk factors associated with a
prothrombotic, proinflammatory and hypofibrinolysis state. Although resistance to tissue …
prothrombotic, proinflammatory and hypofibrinolysis state. Although resistance to tissue …
Cardiometabolic diseases—Recent advance in antithrombotic and thrombolytic therapies
S Nikolovski, W Jeske, J Fareed - Cardiometabolic Diseases, 2025 - Elsevier
In cardiometabolic diseases, sometimes referred as metabolic syndrome (MetS), three
different classes of platelet-inhibiting drugs are used in patient treatment: cyclooxygenase-1 …
different classes of platelet-inhibiting drugs are used in patient treatment: cyclooxygenase-1 …
Effect of erroneous body-weight estimation on outcome of thrombolyzed stroke patients
PR Paliwal, AK Sharma, RN Komal Kumar… - Journal of Thrombosis …, 2020 - Springer
Intravenously administered tissue plasminogen activator (IV-tPA), dose determined by
patients' body-weight, remains the only approved drug treatment for acute ischemic stroke …
patients' body-weight, remains the only approved drug treatment for acute ischemic stroke …
Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis
G Tan, H Wang, S Chen, D Chen, L Zhu, D Xu… - Scientific Reports, 2017 - nature.com
Whether low dose alteplase is comparable to standard dose in efficacy and safety for
intravenous thrombolysis (IVT) in Asian stroke patients remains unverified. PubMed …
intravenous thrombolysis (IVT) in Asian stroke patients remains unverified. PubMed …
Maximum intravenous alteplase dose for obese stroke patients is not associated with greater likelihood of worse outcomes
Background IV alteplase is a primary treatment for acute ischemic stroke (AIS) at a weight-
based dose (WBD) of 0.9 mg/kg and maximum dose (MD) of 90 mg. There are conflicting …
based dose (WBD) of 0.9 mg/kg and maximum dose (MD) of 90 mg. There are conflicting …